{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:09:51Z","timestamp":1780492191053,"version":"3.54.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Real-world healthcare data hold the potential to identify therapeutic solutions for progressive diseases by efficiently pinpointing safe and efficacious repurposing drug candidates. This approach circumvents key early clinical development challenges, particularly relevant for neurological diseases, concordant with the vision of the 21st Century Cures Act. However, to-date, these data have been utilized mainly for confirmatory purposes rather than as drug discovery engines. Here, we demonstrate the usefulness of real-world data in identifying drug repurposing candidates for disease-modifying effects, specifically candidate marketed drugs that exhibit beneficial effects on Parkinson\u2019s disease (PD) progression. We performed an observational study in cohorts of ascertained PD patients extracted from two large medical databases, Explorys SuperMart (N = 88,867) and IBM MarketScan Research Databases (N = 106,395); and applied two conceptually different, well-established causal inference methods to estimate the effect of hundreds of drugs on delaying dementia onset as a proxy for slowing PD progression. Using this approach, we identified two drugs that manifested significant beneficial effects on PD progression in both datasets: rasagiline, narrowly indicated for PD motor symptoms; and zolpidem, a psycholeptic. Each confers its effects through distinct mechanisms, which we explored via a comparison of estimated effects within the drug classification ontology. We conclude that analysis of observational healthcare data, emulating otherwise costly, large, and lengthy clinical trials, can highlight promising repurposing candidates, to be validated in prospective registration trials, beneficial against common, late-onset progressive diseases for which disease-modifying therapeutic solutions are scarce.<\/jats:p>","DOI":"10.3389\/fphar.2021.631584","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T10:08:58Z","timestamp":1619086138000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson\u2019s Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Daphna","family":"Laifenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Ozery-Flato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oded","family":"Shaham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Rosen-Zvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirit","family":"Lev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaara","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"B1","unstructured":"2016"},{"key":"B2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/archneur.60.3.387","article-title":"Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study","volume":"60","author":"Aarsland","year":"2003","journal-title":"Arch. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","article-title":"The epidemiology of dementia associated with Parkinson\u2019s disease","volume":"289","author":"Aarsland","year":"2010","journal-title":"Brain Pathol."},{"key":"B4","volume-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"B5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2045","DOI":"10.1212\/WNL.0000000000006576","article-title":"Early predictors of mortality in parkinsonism and Parkinson disease","volume":"91","author":"B\u00e4ckstr\u00f6m","year":"2018","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/pds.4932","article-title":"Trial designs using real\u2010world data: the changing landscape of the regulatory approval process","volume":"29","author":"Baumfeld Andre","year":"2019","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jbi.2016.10.007","article-title":"Semi-supervised learning of the electronic health record for phenotype stratification","volume":"64","author":"Beaulieu-Jones","year":"2016","journal-title":"J. Biomed. Inform."},{"key":"B10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2307\/234610110.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B (Methodological)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jamaneurol.2017.1133","article-title":"Zolpidem for the treatment of neurologic disorders: a systematic review","volume":"74","author":"Bomalaski","year":"2017","journal-title":"JAMA Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.csbj.2019.02.004","article-title":"Psychiatric disorders and oxidative injury: antioxidant effects of zolpidem therapy disclosed in silico","volume":"17","author":"Bortoli","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.amjmed.2015.10.015","article-title":"Mining retrospective data for virtual prospective drug repurposing: L-DOPA and age-related macular degeneration","volume":"129","author":"Brilliant","year":"2016","journal-title":"Am. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1212\/WNL.0b013e318198e0e9","article-title":"Mechanisms compensating for dopamine loss in early Parkinson disease","volume":"72","author":"Brotchie","year":"2009","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.neuropharm.2010.04.014","article-title":"Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects","volume":"59","author":"Buckley","year":"2010","journal-title":"Neuropharmacology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.1426","article-title":"Real-world data for regulatory decision making: challenges and possible solutions for europe","volume":"106","author":"Cave","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"B19","volume-title":"Agency for healthcare research and quality healthcare cost and utilization project (HCUP)","year":"2015"},{"key":"B20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12647","article-title":"A regenerative approach to the treatment of multiple sclerosis","volume":"502","author":"Deshmukh","year":"2013","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson's disease","volume":"22","author":"Emre","year":"2007","journal-title":"Mov Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1176\/appi.neuropsych.15050118","article-title":"Cognitive effects of rasagiline in mild-to-moderate stage Parkinson's disease without dementia","volume":"29","author":"Frakey","year":"2017","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1080\/10715760400017343","article-title":"Antioxidant activity and neuroprotective effects of zolpidem and several synthesis intermediates","volume":"38","author":"Garc\u00eda-Santos","year":"2004","journal-title":"Free Radic. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40263-018-0601-x","article-title":"Novel treatment opportunities against cognitive impairment in Parkinson's disease with an emphasis on diabetes-related pathways","volume":"33","author":"Green","year":"2019","journal-title":"CNS Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.3892\/ijmm.2018.3406","article-title":"Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review)","volume":"41","author":"Guo","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/mds.23738","article-title":"The effects of rasagiline on cognitive deficits in Parkinson\u2019s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study","volume":"26","author":"Hanagasi","year":"2011","journal-title":"Mov. Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jns.2017.01.012","article-title":"Dementia in Parkinson\u2019s disease","volume":"374","author":"Hanagasi","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3233\/JPD-160965","article-title":"Longer duration of MAO-B inhibitor exposure is associated with less clinical decline in Parkinson's disease: an\u00a0Analysis\u00a0of\u00a0NET-PD LS1","volume":"7","author":"Hauser","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/mds.25877","article-title":"Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson\u2019s disease","volume":"29","author":"Hauser","year":"2014","journal-title":"Mov Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov Disord."},{"key":"B31","volume-title":"Causal inference: what if","author":"Hernan","year":"2020"},{"key":"B32","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available: table 1","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1097\/MLR.0b013e31829b1dbd","article-title":"Caveats for the use of operational electronic health record data in comparative effectiveness research","volume":"51","author":"Hersh","year":"2013","journal-title":"Med. Care"},{"key":"B34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1145\/2623330.2623658","article-title":"Marble: high-throughput phenotyping from electronic health records via sparse nonnegative tensor factorization","volume-title":"Proceedings of the 20th ACM SIGKDD international conference on Knowledge discovery and data mining KDD \u201914","author":"Ho","year":"2014"},{"key":"B35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/amiajnl-2012-001145","article-title":"Next-generation phenotyping of electronic health records","volume":"20","author":"Hripcsak","year":"2013","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.4088\/JCP.13m08790","article-title":"Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study","volume":"76","author":"Huang","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease modification in Parkinson's disease: current approaches, challenges, and future considerations","volume":"33","author":"Lang","year":"2018","journal-title":"Mov Disord."},{"key":"B38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41591-019-0739-1","article-title":"iPSC modeling of young-onset Parkinson's disease reveals a molecular signature of disease and novel therapeutic candidates","volume":"26","author":"Laperle","year":"2020","journal-title":"Nat. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(05)66285-X","article-title":"Zolpidem in Parkinson's disease","volume":"350","author":"Lavoisy","year":"1997","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0204413","DOI":"10.1371\/journal.pone.0204413","article-title":"Use of sedative-hypnotics and the risk of Alzheimer's dementia: a retrospective cohort study","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"key":"B41","volume-title":"Learning to diagnose with LSTM recurrent neural networks","author":"Lipton","year":"2017"},{"key":"B42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fneur.2012.00088","article-title":"Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management","volume":"3","author":"Meireles","year":"2012","journal-title":"Front. Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3892\/etm.2018.7129","article-title":"Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: a meta-analysis","volume":"17","author":"Meng","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"\u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson's disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nature14335","article-title":"Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo","volume":"522","author":"Najm","year":"2015","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1586\/ern.09.68","article-title":"Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease","volume":"9","author":"Naoi","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-211-73574-9_15","article-title":"Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers","author":"Naoi","year":"2007"},{"key":"B48","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/mds.21299","article-title":"Accuracy of medicare claims data in identifying Parkinsonism cases: comparison with the medicare current beneficiary survey","volume":"22","author":"Noyes","year":"2007","journal-title":"Mov Disord."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3233\/978-1-61499-753-5-181","article-title":"Fast and efficient feature engineering for multi-cohort analysis of EHR data","volume":"235","author":"Ozery-Flato","year":"2017","journal-title":"Stud. Health Technol. Inform."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1101\/290585","article-title":"Characterizing subpopulations with better response to treatment using observational data\u2014an epilepsy case study","author":"Ozery-Flato","year":"2018","journal-title":"bioRxiv"},{"key":"B52","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jamiaopen\/ooaa048","article-title":"Framework for identifying drug repurposing candidates from observational healthcare data","volume":"3","author":"Ozery-Flato","year":"2020","journal-title":"Jamia Open"},{"key":"B53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13041-017-0340-9","article-title":"Oxidative stress and cellular pathologies in Parkinson's disease","volume":"10","author":"Puspita","year":"2017","journal-title":"Mol. Brain"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/mds.26724","article-title":"Long-term effects of rasagiline and the natural history of treated Parkinson's disease","volume":"31","author":"Rascol","year":"2016","journal-title":"Mov Disord."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e809","DOI":"10.1097\/MD.0000000000000809","article-title":"An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population","volume":"94","author":"Shih","year":"2015","journal-title":"Medicine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1136\/amiajnl-2013-001935","article-title":"A review of approaches to identifying patient phenotype cohorts using electronic health records","volume":"21","author":"Shivade","year":"2014","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"B57","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural Transm."},{"key":"B58","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JPD-130230","article-title":"The role of oxidative stress in Parkinson's disease","volume":"3","author":"Vera","year":"2013","journal-title":"J. Parkinson\u2019s Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/mds.26617","article-title":"Rasagiline for mild cognitive impairment in Parkinson's disease: a placebo-controlled trial","volume":"31","author":"Weintraub","year":"2016","journal-title":"Mov Disord."},{"key":"B60","volume-title":"WHO collaborating centre for drug statistics methodology: ATC classification index with DDDs","year":"2020"},{"key":"B61","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/sj.mp.4002064","article-title":"Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes","volume":"13","author":"Xiao","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"B62","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/amiajnl-2014-002649","article-title":"Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality","volume":"22","author":"Xu","year":"2014","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"B63","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jpsychires.2014.07.003","article-title":"Zolpidem and the risk of Parkinson's disease: a nationwide population-based study","volume":"58","author":"Yang","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/btt.s2266","article-title":"Mycophenolate mofetil in the treatment of lupus nephritis","volume":"2","author":"Yong","year":"2008","journal-title":"Biologics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.631584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T10:09:19Z","timestamp":1619086159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.631584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":64,"alternative-id":["10.3389\/fphar.2021.631584"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.631584","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.11.20171447","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"article-number":"631584"}}